ARSA and cancer: In general, the results indicated that the PARP1/ACTB and PARP2/ACTB mRNA cellular content ratios are notably increased (t-test, p < 0.001) in most cases and for all tested cancer cell lines after treatment with the alkylators ASA-A, ASA-B, ASA-C and POPA.